by Raynovich Rod | May 9, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-3 11:20a 5/17. Large Caps continue to Look Good; Defensive with dividends and a little growth. ~1% movers as of mid-day trading: AZN, BIIB,GILD, GSK, REGN. IBB lags. Update-2 1:15p EDT Biotech stocks remain sluggish as NASDAQ rally slumps to red. Large caps...
by Raynovich Rod | Mar 8, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update on rally day 3/9/21 1:22p Biotech and Healthcare Movers per Post Tech stocks rally on reversal trade. Biopharma positioned between value and moderate growth. COVID Vaccine stocks all up big BNTX CVAC NVAX MRNA. Small caps continue in uptrend ; IJR IWC IWM....
by Raynovich Rod | Mar 3, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Macro
Update-1 3/5/21…2:30p-Large Cap Biopharmas Firming Up See our last Large Cap Review . IBB up 0.73% at $148 handle. Regeneron up 3% off bottom, FWD PE 11.31, P/S 5.7, 11.75 QtQ sales growth . Nice moves in AMGN, BIIB, GILD, GSK, LLY. Review your large caps!...
by Raynovich Rod | Feb 22, 2021 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
by Raynovich Rod | Feb 7, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 FEB 11, Momentum easing with some good stocks moves, XBI off 1.3% to $165.83. Coronavirus focus stocks are mixed with our holdings doing well. ABT up 1.24%, HOLX up 0.53% and Genmark Diagnostics (GNMK) up 33% to $22.46 on rumors of being acquired, but...
by Raynovich Rod | Jan 25, 2021 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
1/28/21 Update-2 VIR Hits $140 yesterday then rolls over to $58+ today! JPMorgan downgraded VIR letting some of the air out of the ballon. The recent speculation may have been about a VIR antibody mirroring the therapeutic potential of the Lilly (LLY) developments....
by Raynovich Rod | Jan 1, 2021 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 Jan 5, 2021 Nice Reversal to the Upside! Energy stocks rock! NASDAQ moved up 1% and the S&P followed up 0.71% both near highs of the day. Energy stocks were a big gainer with the XLE up 4.5% and the metals ETF up 5%(XME) a new trend in materials and...
by Raynovich Rod | Dec 14, 2020 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1. 12/15…With Biden being declared a winner the focus of macro turns to stimulus talks and the FED Meeting tomorrow. The market ebullience returned today with all major indices up over 1%. The Pfizer vaccine is rolling out with Moderna expected next. With...
by Raynovich Rod | Dec 6, 2020 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-4 12/10….Nice snapback rally in NASDAQ up 0.54% with many nice moves in gene therapy from ASH. XBI up 3.69% ASH gives us two big wins : EDIT up 32% on IND application for sickle disease; Sangamo (SGMO) up 50% on Hemophilia A gene therapy. Gene therapy...
by Raynovich Rod | Nov 29, 2020 | 2024-25 Life Science Portfolios, Biopharmaceuticals
November Rally in Biotech and with Broadening to Other Sectors Small caps taking off including XBI up 12%, IWM up 16.5% (11.2% YTD). Healthcare lagging a bit with the XLV up only 3.35% vs SPY up 7.5% (12.6% YTD). Re-openng trade movers: XLI up 14.75% at $88.11; XLE...
